Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to ...

A secondary analysis of a large trial shows that exposure to the HIV drug abacavir is linked to an elevated risk for major ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...

Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between US ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Several Midwestern Cities have been designated as HIV “hotspots” due to the rising number of new cases; and the South ...

Rep. Marjorie Taylor Greene (R-GA) ranted about how the U.S. sends money to Africa to prevent the spread of HIV, arguing that ...

People living with HIV face unique oral health challenges that require special attention and care. The virus's impact on the ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

A pivotal moment in the fight to end AIDS -- ensuring lifesaving innovation reaches those who need it most, wherever they liveThe Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) ...

Gilead Sciences, in partnership with the Global Fund, plans to supply a long-acting HIV prevention drug to low-income ...